Search
for

    Sort by

    Community Join

    990-1000 / 1000+ results

      community 6 months before and after pics: VDPHL01 (oral minoxidil)

      in Progress Pictures  111 upvotes 1 year ago
      A user shared their positive experience with a clinical trial for a new oral medication, VDPHL01, which is a reformulated version of oral minoxidil taken at a high dose of 17mg daily, showing significant hair regrowth after six months. The user noted that this formulation is believed to be more effective and time-released, with fewer side effects compared to regular oral minoxidil.

      community GT20029 Anageninc Market Availability

      in Research/Science  164 upvotes 3 years ago
      The conversation discusses the potential market release of a hair loss treatment called GT20029 by Anageninc, with users expressing interest and discussing the importance of safety and effectiveness. Some users plan to contact Anageninc to show demand for the product.

      community 5mg KX 826 Worked. Will 2.5mg Hold?

      in Technology  6 upvotes 1 year ago
      Reducing the dose of Pyrilutamide from 5mg to 2.5mg may still maintain hair loss results, but effectiveness can vary. Users discuss the cost and dosage implications, with some cautioning against reducing the dose due to its dose-dependent nature.

      community Ru 58841 and essential oils question

      in Treatment  3 upvotes 5 years ago
      The user discusses using essential oils like peppermint, rosemary, tea tree, and lavender to improve hair thickness and seborrheic dermatitis. They plan to add RU58841 to their routine and seek advice on using it alongside the essential oils without interference.

      community Prediction: Scube3 is never coming out

      in Research/Science  6 upvotes 2 years ago
      Scube3, a potential hair loss treatment, is unlikely to be released because it was given to a startup company, Amplifica, which may go bankrupt and fail to bring the treatment to market. Amplifica is prioritizing other treatments over Scube3, which could lead to financial loss and the end of Scube3's development.